PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity
- PMID: 33500712
- PMCID: PMC7797685
- DOI: 10.7150/thno.50701
PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity
Abstract
Synapses are the functional units of the brain. They form specific contact points that drive neuronal communication and are highly plastic in their strength, density, and shape. A carefully orchestrated balance between synaptogenesis and synaptic pruning, i.e., the elimination of weak or redundant synapses, ensures adequate synaptic density. An imbalance between these two processes lies at the basis of multiple neuropathologies. Recent evidence has highlighted the importance of glia-neuron interactions in the synaptic unit, emphasized by glial phagocytosis of synapses and local excretion of inflammatory mediators. These findings warrant a closer look into the molecular basis of cell-signaling pathways in the different brain cells that are related to synaptic plasticity. In neurons, intracellular second messengers, such as cyclic guanosine or adenosine monophosphate (cGMP and cAMP, respectively), are known mediators of synaptic homeostasis and plasticity. Increased levels of these second messengers in glial cells slow down inflammation and neurodegenerative processes. These multi-faceted effects provide the opportunity to counteract excessive synapse loss by targeting cGMP and cAMP pathways in multiple cell types. Phosphodiesterases (PDEs) are specialized degraders of these second messengers, rendering them attractive targets to combat the detrimental effects of neurological disorders. Cellular and subcellular compartmentalization of the specific isoforms of PDEs leads to divergent downstream effects for these enzymes in the various central nervous system resident cell types. This review provides a detailed overview on the role of PDEs and their inhibition in the context of glia-neuron interactions in different neuropathologies characterized by synapse loss. In doing so, it provides a framework to support future research towards finding combinational therapy for specific neuropathologies.
Keywords: cell-signaling; glia-neuron; neurodegeneration; phosphodiesterase; synapses.
© The author(s).
Conflict of interest statement
Competing Interests: TV and JP have a proprietary interest in selective PDE4D inhibitors for the treatment of demyelinating disorders. JP has a proprietary interest in the PDE4 inhibitor roflumilast for the treatment of cognitive impairment. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.Neurosci Lett. 1998 Aug 7;252(1):57-60. doi: 10.1016/s0304-3940(98)00551-5. Neurosci Lett. 1998. PMID: 9756358
-
Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.Exp Biol Med (Maywood). 2007 Jan;232(1):38-51. Exp Biol Med (Maywood). 2007. PMID: 17202584 Review.
-
Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.Handb Exp Pharmacol. 2011;(204):447-85. doi: 10.1007/978-3-642-17969-3_19. Handb Exp Pharmacol. 2011. PMID: 21695652 Review.
-
The role of phosphodiesterases in schizophrenia : therapeutic implications.CNS Drugs. 2008;22(12):983-93. doi: 10.2165/0023210-200822120-00002. CNS Drugs. 2008. PMID: 18998737 Review.
-
PDE2 at the crossway between cAMP and cGMP signalling in the heart.Cell Signal. 2017 Oct;38:76-84. doi: 10.1016/j.cellsig.2017.06.020. Epub 2017 Jun 28. Cell Signal. 2017. PMID: 28668721 Review.
Cited by
-
Phosphodiesterase inhibitors in psychiatric disorders.Psychopharmacology (Berl). 2023 Jun;240(6):1201-1219. doi: 10.1007/s00213-023-06361-3. Epub 2023 Apr 15. Psychopharmacology (Berl). 2023. PMID: 37060470 Review.
-
Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.Brain. 2023 Mar 1;146(3):898-911. doi: 10.1093/brain/awac136. Brain. 2023. PMID: 35411386 Free PMC article.
-
Circadian rhythm disruptions associated with opioid use disorder in synaptic proteomes of human dorsolateral prefrontal cortex and nucleus accumbens.Mol Psychiatry. 2023 Nov;28(11):4777-4792. doi: 10.1038/s41380-023-02241-6. Epub 2023 Sep 6. Mol Psychiatry. 2023. PMID: 37674018 Free PMC article.
-
Neuroinflammation in Ischemic Stroke: Inhibition of cAMP-Specific Phosphodiesterases (PDEs) to the Rescue.Biomedicines. 2021 Jun 22;9(7):703. doi: 10.3390/biomedicines9070703. Biomedicines. 2021. PMID: 34206420 Free PMC article. Review.
-
Protective effects of docosahexaenoic acid supplementation on cognitive dysfunction and hippocampal synaptic plasticity impairment induced by early postnatal PM2.5 exposure in young rats.Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6563-6575. doi: 10.1007/s00210-024-03028-4. Epub 2024 Mar 9. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38459987
References
-
- Rakic P, Bourgeois JP, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science. 1986;232:232–5. - PubMed
-
- Argyrousi EK, Heckman PR, van Hagen BT, Muysers H, van Goethem NP, Prickaerts J. Pro-cognitive effect of upregulating cyclic guanosine monophosphate signalling during memory acquisition or early consolidation is mediated by increased AMPA receptor trafficking. J Psychopharmacol. 2020;34:103–14. - PMC - PubMed
-
- Argyrousi EK, Heckman PRA, Prickaerts J. Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot. Neurosci Biobehav Rev. 2020;113:12–38. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources